JP2002514072A - 突然変異誘発を指示する相同組み換えのためのベクターの構築の方法 - Google Patents
突然変異誘発を指示する相同組み換えのためのベクターの構築の方法Info
- Publication number
- JP2002514072A JP2002514072A JP53687598A JP53687598A JP2002514072A JP 2002514072 A JP2002514072 A JP 2002514072A JP 53687598 A JP53687598 A JP 53687598A JP 53687598 A JP53687598 A JP 53687598A JP 2002514072 A JP2002514072 A JP 2002514072A
- Authority
- JP
- Japan
- Prior art keywords
- vector
- genomic dna
- yeast
- coli
- positive selection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 title claims abstract description 105
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000010276 construction Methods 0.000 title claims abstract description 23
- 238000002744 homologous recombination Methods 0.000 title claims abstract description 21
- 230000006801 homologous recombination Effects 0.000 title claims abstract description 21
- 238000002703 mutagenesis Methods 0.000 title claims abstract description 18
- 231100000350 mutagenesis Toxicity 0.000 title claims abstract description 18
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 5
- 108020004414 DNA Proteins 0.000 claims description 65
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 55
- 241000588724 Escherichia coli Species 0.000 claims description 35
- 239000013612 plasmid Substances 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 238000003780 insertion Methods 0.000 claims description 21
- 230000037431 insertion Effects 0.000 claims description 20
- 108091008146 restriction endonucleases Proteins 0.000 claims description 20
- 238000010367 cloning Methods 0.000 claims description 17
- 230000006798 recombination Effects 0.000 claims description 16
- 238000005215 recombination Methods 0.000 claims description 16
- 210000004102 animal cell Anatomy 0.000 claims description 14
- 239000003550 marker Substances 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 12
- 210000004962 mammalian cell Anatomy 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 239000013605 shuttle vector Substances 0.000 claims description 12
- 241000701959 Escherichia virus Lambda Species 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 108010091086 Recombinases Proteins 0.000 claims description 7
- 102000018120 Recombinases Human genes 0.000 claims description 7
- 238000003776 cleavage reaction Methods 0.000 claims description 7
- 230000007017 scission Effects 0.000 claims description 7
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 230000008774 maternal effect Effects 0.000 claims description 3
- 210000004291 uterus Anatomy 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims 2
- 230000005868 ontogenesis Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 241000206602 Eukaryota Species 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 1
- 108010042407 Endonucleases Proteins 0.000 description 13
- 102100031780 Endonuclease Human genes 0.000 description 12
- 101150050575 URA3 gene Proteins 0.000 description 12
- 239000013615 primer Substances 0.000 description 12
- 230000010076 replication Effects 0.000 description 11
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 108010051219 Cre recombinase Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241001190694 Muda Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 101150006914 TRP1 gene Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000007702 DNA assembly Methods 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042546 GCGGCCGC-specific type II deoxyribonucleases Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101000626625 Staphylococcus aureus Type II restriction enzyme Sau3AI Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- JPIYZTWMUGTEHX-UHFFFAOYSA-N auramine O free base Chemical compound C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 JPIYZTWMUGTEHX-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108010049708 endonuclease S Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 101150006217 lex1 gene Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- -1 texa red Chemical compound 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19707012 | 1997-02-21 | ||
| DE19707012.4 | 1997-02-21 | ||
| PCT/US1998/003243 WO1998037175A1 (fr) | 1997-02-21 | 1998-02-20 | Procede servant a construire des vecteurs de recombinaison homologue pour une mutagenese dirigee |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002514072A true JP2002514072A (ja) | 2002-05-14 |
Family
ID=7821111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53687598A Pending JP2002514072A (ja) | 1997-02-21 | 1998-02-20 | 突然変異誘発を指示する相同組み換えのためのベクターの構築の方法 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0912722A4 (fr) |
| JP (1) | JP2002514072A (fr) |
| WO (1) | WO1998037175A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU777909B2 (en) | 1999-01-19 | 2004-11-04 | Lexicon Genetics Incorporated | Mammalian cortexin-like proteins and polynucleotides encoding the same |
| WO2000055311A2 (fr) * | 1999-03-17 | 2000-09-21 | E.I. Du Pont De Nemours And Company | Modification genique par recombinaison homologue |
| US6548271B1 (en) | 1999-04-22 | 2003-04-15 | Lexicon Genetics Incorporated | Nucleic acids encoding human transporter proteins |
| EP1222269A1 (fr) | 1999-10-12 | 2002-07-17 | Lexicon Genetics Incorporated | Proteines humaines de la famille des recepteurs de ldl et polynucleotides les codant |
| DE10016523A1 (de) * | 2000-04-03 | 2001-10-04 | Ingenium Pharmaceuticals Ag | Klonierungssystem zur Konstruktion von homologen Rekombinationsvektoren |
| US20020031829A1 (en) * | 2000-08-15 | 2002-03-14 | Brian Zambrowicz | Arrayed collection of genomic clones |
| SG164274A1 (en) * | 2000-08-25 | 2010-09-29 | Pfizer Prod Inc | Rapid creation of gene targeting vectors using homologous recombination in yeast |
| US6376192B1 (en) | 2000-11-28 | 2002-04-23 | Baylor College Of Medicine | Method for screening of DNA libraries and generation of recombinant DNA constructs |
| DE10133928A1 (de) * | 2001-07-12 | 2003-01-23 | Bayer Cropscience Ag | Verfahren zum Herstellen von Deletionsmutanten |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09509046A (ja) * | 1993-11-29 | 1997-09-16 | ユニヴァーシティ オブ サウス フロリダ | トランスジェニックマウス |
-
1998
- 1998-02-20 EP EP98908603A patent/EP0912722A4/fr not_active Withdrawn
- 1998-02-20 JP JP53687598A patent/JP2002514072A/ja active Pending
- 1998-02-20 WO PCT/US1998/003243 patent/WO1998037175A1/fr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998037175A1 (fr) | 1998-08-27 |
| EP0912722A1 (fr) | 1999-05-06 |
| EP0912722A4 (fr) | 2001-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3832851B2 (ja) | 人工トランスポゾンのｉｎｖｉｔｒｏにおける転位 | |
| US7629326B2 (en) | Chromosomal modification involving the induction of double-stranded DNA cleavage and homologous recombination at the cleavage site | |
| JP4999293B2 (ja) | 人工染色体、該染色体の使用および人工染色体の製造方法 | |
| JP5124539B2 (ja) | 人工染色体、該染色体の使用および人工染色体の製造方法 | |
| US7160682B2 (en) | Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell | |
| JP3298842B2 (ja) | 外来性遺伝子のゲノム上部位特異的挿入により作製されたトランスジェニック又はキメラ動物 | |
| AU2004204167B2 (en) | Targeted transgenesis using the Rosa26 locus | |
| Westphal et al. | Transposon-generated ‘knock-out’and ‘knock-in’gene-targeting constructs for use in mice | |
| JP7418796B2 (ja) | 細胞株の開発のための相同組換えベクターの高速生成のためのｄｎａプラスミド | |
| JP2002514072A (ja) | 突然変異誘発を指示する相同組み換えのためのベクターの構築の方法 | |
| JP2004530429A (ja) | 転写活性な座を標的化する方法 | |
| US7285699B2 (en) | Ends-out gene targeting method | |
| US6924146B1 (en) | Method of constructing vectors for homologous recombination directed mutagenesis | |
| US6090629A (en) | Efficient construction of gene targeting using phage-plasmid recombination | |
| US20030121063A1 (en) | Compositions and methods of use of mammalian retrotransposons | |
| TWI704224B (zh) | 編輯核酸序列之組成物及方法 | |
| KR102403995B1 (ko) | 파킨슨 병 유도 벡터 및 이를 이용한 개 모델의 제조 방법 | |
| KR20240002710A (ko) | 부위 특이적 넉인 시스템 (Site-specific Knock-in(KI)system)을 이용한 형질전환 소 생산 방법 | |
| Ostertag | Insights into the mechanism of* L1 retrotransposition | |
| Voet | Design and Characterization of a Chromosomal Vector for Transgenesis in Higher Eukaryotes | |
| JPH1014571A (ja) | 突然変異誘発方法、突然変異誘発遺伝子、トランスジェニック生物、及びその生産方法 |